Mark Andrew Wilson has sold NKTR and made no open-market buys since May 2020

Mark Andrew Wilson is a corporate attorney and biotechnology industry executive who has served as Senior Vice President and Chief Legal Officer/General Counsel at Nektar Therapeutics (NASDAQ: NKTR), where he was a reporting corporate insider.( At Nektar, his responsibilities have included overseeing the company’s legal function and broader corporate matters, and he has been listed in company and SEC materials as Chief Legal Officer and a member of the executive leadership team.( In November 2025, Nektar disclosed that Wilson would step down from his Chief Legal Officer role effective December 31, 2025, in an orderly leadership transition.(

Wilson brings more than 25 years of pharmaceutical and biotechnology experience, having joined Nektar in the early 2000s and led major global development and commercialization collaborations, strategic corporate transactions, alternative financings, and the company’s global patent strategy.( Before Nektar, he worked as an associate at Reed & Associates, a patent law firm in Menlo Park, California.( He holds a J.D. from Seton Hall University School of Law and a B.S. in Pharmacy from Rutgers University College of Pharmacy, and is registered to practice before the U.S. Patent and Trademark Office as well as being a member of the State Bar of California.( Following his tenure at Nektar, Wilson was appointed Chief Legal Officer at Septerna, Inc., a clinical-stage biotechnology company focused on GPCR-targeted drug discovery, where he continues to apply his expertise in intellectual property, strategic collaborations, and corporate governance.(

Written by Perplexity from public sources.